Inner Cosmos

Treating Depression With Neurotechnology

About this Event

Inner Cosmos has created the world’s first digital treatment for the 7 million patients with drug resistant depression.

Inner Cosmos was recently featured in Forbes, where the author went deep into the company’s history, its groundbreaking technology, and spoke to a clinical trial patient about the impact their device has had on his life. You can read the full story here.

Depression is the leading cause of disability worldwide with more than 21 million people in the U.S. under treatment, but for 30% of patients current drugs offer no relief. One FDA-approved solution, Transcranial Magnetic Stimulation (TMS), is highly effective but requires 30 continuous days of in-hospital treatment every 6 to 12 months, which is not logistically feasible for many patients.

Inner Cosmos is the first implantable depression technology in 20 years to be tested in a clinical setting. The company expects to complete its safety study with this seed investment. Inner Cosmos will initiate a pivotal study in 2026 to get its therapy approved by the FDA and on the market as soon as possible.

Register today to join this Fireside Chat with Inner Cosmos co-founder and CEO, Meron Gribetz, to learn more about how their “TMS to go” digital device has the potential to change the lives of millions of people who suffer from depression.

Video On Demand

– Recorded

April 23

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.